Review Article
Pharmacological Management of Cardiorenal Syndromes

Andrew A. House,1,2 Mikko Haapio,3 Johan Lassus,4 Rinaldo Bellomo,5 and Claudio Ronco6

1 Division of Nephrology, London Health Sciences Centre, University Hospital, 339 Windermere Road, London, ON, Canada N6A 5A5
2 Division of Nephrology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada N6A 3K7
3 Division of Nephrology, HUCH Meilahti Hospital, P.O. Box 340, Helsinki FI-00029, Finland
4 Division of Cardiology, HUCH Meilahti Hospital, P.O. Box 340, Helsinki FI-00029, Finland
5 Department of Intensive Care, Austin Hospital, Melbourne VIC 3084, Australia
6 Department of Nephrology, San Bortolo Hospital, International Renal Research Institute Vicenza (IRRIV), Viale Rodolfi 37, Vicenza 36100, Italy

Correspondence should be addressed to Andrew A. House, andrew.house@lhsc.on.ca

Received 10 August 2010; Accepted 28 March 2011

Academic Editor: Anjay Rastogi

Copyright © 2011 Andrew A. House et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiorenal syndromes are disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. The pharmacological management of Cardiorenal syndromes may be complicated by unanticipated or unintended effects of agents targeting one organ on the other. Hence, a thorough understanding of the pathophysiology of these disorders is paramount. The treatment of cardiovascular diseases and risk factors may affect renal function and modify the progression of renal injury. Likewise, management of renal disease and associated complications can influence heart function or influence cardiovascular risk. In this paper, an overview of pharmacological management of acute and chronic Cardiorenal Syndromes is presented, and the need for high-quality future studies in this field is highlighted.

1. Introduction

Cardiorenal syndromes (CRS) affect a broad array of patients in both acute and chronic clinical situations, with significant ramifications in terms of morbidity and mortality. For instance, type 1 CRS, as seen in patients experiencing an abrupt increase in serum creatinine >0.3 mg/dL (>26 μmol/L) during hospitalization for acute decompensated heart failure (ADHF), is associated with increased length of stay, more complications, and higher mortality. In chronic heart failure, the coexistence of chronic kidney disease (CKD) with glomerular filtration rate (GFR) <60 mL/min/1.73 m² (type 2 CRS) significantly increases the risk for mortality. Acute kidney injury, for example, following contrast for radiological imaging, has been associated with subsequent adverse cardiovascular events, so-called type 3 CRS. Numerous studies have identified CKD as a graded and independent risk factor for cardiovascular events and outcomes, representing type 4 CRS. Systemic disorders that involve both the heart and kidneys (type 5 CRS) are a heterogeneous group, but when examining sepsis as an example, increasing numbers of organs involved dramatically increases mortality, particularly in those with evidence of septic cardiomyopathy [1] and acute kidney injury [2].

In this paper, we review briefly the pharmacological management of the various subtypes of CRS, highlighting the need for high-quality future studies. Table 1 presents a point-form summary of suggested management for these subtypes, along with pitfalls and questions for future research.

2. Management of Acute Cardiorenal Syndrome (Type 1)

Type 1 CRS appears in the setting of ADHF or cardiogenic shock for a number of reasons, with hemodynamic...
| CRS subtype                        | General considerations and recommended therapies                                                                 | Caveats/areas for future investigation                                                                 |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| **Acute cardio-renal (CRS 1)**    | - Reduce congestion with diuretics, balance negative fluid balance with intravascular refilling.                  | - Infusion versus bolus; dose; electrolyte concerns                                                   |
|                                   | - Renin-angiotensin blockade may need to be reduced or even withheld with worsening renal function.               | - Limited data from uncontrolled trials; nitroprusside limited by toxicity                            |
|                                   | - With preserved or elevated blood pressure, empiric use of vasodilators                                           | - Conflicting results of clinical trials; ongoing trials to determine safety, efficacy, and dose     |
|                                   | - Nesiritide may improve cardiac output and cause significant diuresis                                               | - Intropes may provoke ischemia or arrhythmia; increased mortality in some studies; mechanical support |
|                                   | - With low pressure, poor cardiac output, inotropes may be required as a bridge to recovery or transplantation        | (balloon pump, ventricular assist device, etc.) may be required                                       |
| **Chronic cardio-renal (CRS 2)**  | - Renin-angiotensin blockade is of primary importance; may need to be reduced or withheld with significantly worsening renal function | - Most studies have excluded patients with significant kidney disease; increase in creatinine >30% or potassium >5.0 mmol/L cause for concern |
|                                   | - Aldosterone antagonists may be cautiously considered                                                              | - Creatinine >2.5 mg/dL (>220 μmol/L) or potassium >5.0 mmol/L were exclusions in clinical trials    |
|                                   | - Beta-blockers are important adjuncts in congestive heart failure and/or ischemic heart disease                     | - Some agents (atenolol, nadolol, sotalol) have altered pharmacokinetics; carvedilol may have an advantage over older drugs |
|                                   | - Concomitant anemia may worsen symptoms and outcomes                                                              | - Unclear role of erythropoiesis-stimulating agents; parenteral iron encouraging in terms of symptoms as well as improved renal function |
| **Acute reno-cardiac (CRS 3)**    | - Contrast nephropathy is a common example of CRS 3; prevention is likely the best strategy.                       | - Preexisting chronic kidney disease, age, diabetes, and volume contraction are amongst risks that predispose to contrast nephropathy |
|                                   | - Numerous strategies tested; isotonic fluids and possibly N-acetylcysteine have the best evidence to date        |                                                                                                        |
|                                   | - Low osmolar, nonionic contrast may reduce risk of CRS 3                                                          |                                                                                                        |
| **Chronic reno-cardiac (CRS 4)**  | - Multifaceted disorder with both traditional and non-traditional risk factors; graded risk based on degree of chronic kidney disease | - Lifestyle modification (smoking, weight control, activity, and nutrition) of probable benefit but limited evidence |
|                                   | - Anemia closely related to poor outcomes; current guidelines recommend starting for sustained hemoglobin <10 g/dL (100 g/L) and targeting 10–12 g/dL (100–120 g/L) | - Studies showed increased harm from higher targets; concerns have been raised about stroke risk, and risk in patients with cancer |
|                                   | - Management of chronic kidney disease-related mineral and bone disorders; phosphate binders, vitamin D analogs, controlling PTH | - As yet, efficacy largely limited to putative surrogate endpoints; ongoing trials with hard cardiovascular endpoints awaited |
|                                   | - Lipid lowering with statins                                                                                      | - Efficacy in dialysis-dependent patients is questioned; in lesser degrees of chronic kidney disease risk reduction is clearly established |
| **Secondary cardio-renal (CRS 5)**| - Sepsis is a common example of CRS 5; management needs to focus on protecting/optimizing both cardiac and renal function | - Other secondary causes of CRS 5 are a fruitful area for ongoing research                              |
|                                   | - Volume and pressor support to achieve a mean arterial pressure ≥65 mmHg and central venous pressure of 8 to 12 mmHg and adequate oxygen delivery | - Early protocol-driven interventions lower risk of adverse renal outcomes and death due to cardiovascular collapse |
|                                   | - Norepinephrine preferred over dopamine in a randomized controlled trial (most patients had septic shock)      | - Higher incidence of cardiac arrhythmia and trend to increased need for dialysis with dopamine      |
|                                   | - Addition of low-dose vasopressin in select patients                                                              | - May decrease risk of adverse cardiac and renal outcomes                                             |
derangements ranging from acute pulmonary edema with hypertension through severe peripheral fluid overload to cardiogenic shock and hypotension [3–5]. Unfortunately, the management of type 1 CRS is largely empiric, as many of the traditional therapies to relieve congestive and/or ischemic symptoms (diuretics, vasodilators, and morphine) [5] have not been subjected to rigorous study. While hypotension and decreased cardiac output with neurohormonal activation have been the traditional explanations for worsening renal function in this setting, recent evidence has implicated high venous pressure and raised intra-abdominal pressure leading to renal venous congestion as important contributors to impairment of kidney function [6, 7], and indeed many patients with ADHF and type 1 CRS have preserved left ventricular ejection fraction and normal or high blood pressure. Hence, strategies to reduce congestion with diuretics and possibly ultrafiltration, and the use of vasodilators in select patients, are important steps in early management.

The goal of diuretic use should be to deplete the extracellular fluid volume at a rate that allows adequate time for intravascular refilling from the interstitium. To achieve adequate diuresis, infusions of loop diuretics have been demonstrated to have greater efficacy than intermittent dosing [8], and certainly loop diuretics are preferred to thiazides, whose actions are diminished in patients with impaired kidney function [9]. In a recent study, ADHF patients who developed hemococoncentration during diuresis (presumed to be diuresed in excess of refilling rate) did in fact have a greater risk of worsening renal function with an odds ratio of 5.3 (P < .001), however they also had lower 180-day mortality, with a hazard ratio of 0.31 (P = .013) [10]. Diuretics may hence need to be withheld or reduced to allow for plasma refilling. Finding the optimal balance between relief of ADHF symptoms while maintaining adequate kidney function will require further study, and the optimal dose and route of loop diuretic is being studied in the randomized trial DOSE-AHF [11].

If kidney function continues to worsen, blockade of the renin-angiotensin-aldosterone-system (RAAS) may be a contributing factor, necessitating withholding or delaying the introduction of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in order to maintain the GFR [12]. As a nonpharmacological strategy to more vigorously manage hypervolemia and circulatory congestion, ultrafiltration was demonstrated in the UNLOAD study to be superior to diuretics, in terms of greater weight loss, less requirement for vasoactive drugs, and fewer readmissions and emergency room visits, with no difference in mortality [13]. The CARRRESS-HF trial is currently being undertaken to further define the use of this therapy in patients with type 1 CRS [11].

For type 1 CRS patients with preserved or elevated blood pressure, vasodilators such as nitroglycerin and nitroprusside are often used to relieve symptoms and improve hemodynamics [14], though their efficacy has not been studied through randomized controlled trials, and their effect on reversing or preventing type 1 CRS is unknown. The use of nitroprusside in patients with impaired kidney function is potentially hazardous due to the accumulation of thiocyanate [15], however, in a nonrandomized trial which included patients with varying degrees of kidney function, its use was associated with improved outcomes and stable kidney function [16].

Nesiritide, a recombinant form of human B-type natriuretic peptide, quickly relieves dyspnea in acute heart failure states, through a combination of decreased preload, afterload and pulmonary vascular resistance, and increased cardiac output. It also causes a brisk diuresis due to direct renal effects including afferent arteriolar vasodilation and decreased sodium reabsorption [17]. However, a meta-analysis of trials in patients with ADHF found that nesiritide did not avert type 1 CRS and increased mortality [18]. Ongoing research will hopefully clarify its role in type 1 CRS [19].

When patients have low blood pressure and poor renal perfusion, positive inotropes such as dobutamine or phosphodiesterase inhibitors may be required [5]. However, the use of inotropes may actually accelerate some harmful processes such as ischemia or arrhythmia. Milrinone, for instance, was demonstrated to have a higher incidence of hypotension, more arrhythmias, and no benefit on mortality or hospitalization in ADHF patients [20]. Levosimendan, a phosphodiesterase inhibitor with calcium sensitizing activity, has shown mixed results in terms of the prevention and treatment of type 1 CRS [21, 22]. When patients with ADHF or cardiogenic shock and type 1 CRS are resistant to therapy, more invasive therapies such as intra-aortic balloon pulsation, ventricular assist devices, or artificial hearts may be required as a bridge to recovery of cardiac function or to transplantation.

Finally, a number of classes of agents targeting some of the vasoactive/neurohormonal effector pathways in type 1 CRS, specifically endothelin, adenosine, and vasopressin, have held promise in preclinical and early clinical trials. However, subsequent randomized trials have failed to show a benefit of antagonism of receptors for these targets [23–26].

3. Management of Chronic Cardiorenal Syndrome (Type 2)

Interruption of the RAAS is the primary goal in the management of type 2 CRS. However, RAAS blockade can lead to significant decrease in kidney function, and/or elevated potassium. Studies of RAAS blockade in heart failure have typically excluded CKD patients [27], but it is likely that these agents are renoprotective even in this population. The CONSENSUS trial, for example, included a number of subjects whose serum creatinine increased by 30% or greater with enalapril [28]. However, creatinine tended to stabilize in many instances improved over the course of the study. Typically it is recommended that RAAS blockade may be carefully titrated provided the serum creatinine does not continue to rise beyond 30% and potassium is consistently below 5.0 mmol/L.

In terms of aldosterone blockade, drugs such as spironolactone and eplerenone are an important adjunct to therapy in patients with severe heart failure [29, 30]. However, the use of these agents in patients with CKD, and particularly in combination with other RAAS blockade, can dramatically
increase the risk of hospitalizations and mortality secondary to hyperkalemia [31]. Excluding patients with moderate CKD (creatinine level ≥2.5 mg/dL or 220 μmol/L) or hyperkalemia >5.0 mmol/L, which were exclusion criteria in the Randomized Aldactone Evaluation Study (RALES) [29], will minimize potential life-threatening complications [32].

 Interruption of sympathetic tone through the use of beta-blockers is another important strategy for patients with congestive heart failure or ischemic heart disease. In general, these drugs should not adversely affect kidney function. Certain beta-blockers may be relatively contraindicated in CKD because of altered pharmacokinetics, such as atenolol, nadolol, or sotalol [33], and it is wise to consult a pharmacopoeia when prescribing beta-blockers to patients with CKD. Carvedilol, a beta-blocker with α1 blocking effects, has been demonstrated to have favourable effects on kidney function in some CRS patients, hence may have a benefit over older beta-blockers [34].

 Both congestive heart failure and CKD are associated with anemia, the latter of which is commonly treated with erythropoiesis-stimulating agents. Furthermore, the action of erythropoietin in the heart may reduce apoptosis, fibrosis, and inflammation [35, 36]. Hence, there has been intense interest in using erythropoiesis-stimulating agents in heart failure patients [37]. A small controlled trial suggested that administration of erythropoiesis-stimulating agents in patients with type 2 CRS and anemia led to improved cardiac function, reduction in left ventricular size, and lowering of BNP [38]. However, more recent work did not find significant improvement in a variety of important clinical parameters [39]. Ongoing clinical trials are required to establish if erythropoiesis-stimulating agents have a role to play in the management of congestive heart failure and type 2 CRS. Another approach to anemia management in type 2 CRS is parenteral iron. In the FAIR-HF study, patients were randomized to ferric carboxymaltose or placebo, and the active treatment group experienced an improvement in heart failure symptoms, Patient Global Assessment, 6-minute walk test and quality of life [40]. They also experienced a higher GFR at the study conclusion of 3.8 mL/min/1.73 m².

4. Management of Acute Reno-Cardiac Syndrome (Type 3)

In type 3 CRS, acute kidney injury occurs as a primary event (e.g., acute glomerulonephritis) or secondary event (e.g., radiocontrast, exogenous or endogenous nephrotoxins, postsurgical, etc.), and cardiac dysfunction is a common and often times fatal sequela [41]. A common example of type 3 CRS occurring in the hospital setting is contrast nephropathy, particularly in patients undergoing coronary and other angiographic procedures who have risk factors such as preexisting CKD, diabetes, older age or volume contraction. In these susceptible populations, prevention may provide the best opportunity to “treat” or avoid type 3 CRS. Many potential preventive strategies have been studied, including parenteral hydration (hypotonic or isotonic saline or bicarbonate), diuretics, mannitol, natriuretic peptides, dopamine, fenoldopam, theophylline, and N-acetylcysteine [42, 43]. To date, isotonic fluids have been the most successful intervention, with some controversy surrounding the effectiveness of N-acetylcysteine. Using a sensitive definition of acute kidney injury, Solomon and colleagues identified a possible role for the low-osmolar, nonionic monomer iopamidol in the prevention of contrast nephropathy [44]. In addition, they identified that the research subjects who experienced acute kidney injury were almost twice as likely to have major cardiovascular events (death, stroke, myocardial infarction, or dialysis) during the follow-up period, indicative of the seriousness of type 3 CRS.

 Treatment of primary kidney diseases such as acute glomerulonephritis or kidney allograft rejection may potentially lessen the risk of type 3 CRS, but this has not been systematically studied. Furthermore, many immunosuppressive drugs used for such treatment have adverse effects on the cardiovascular system through their effects on blood pressure, lipids, and glucose metabolism. For instance, a recent meta-analysis comparing the calcineurin-inhibitors cyclosporine and tacrolimus found greater dyslipidemia in the cyclosporine group and higher risk of new onset diabetes in the tacrolimus group [45]. The drug sirolimus, working through the mammalian target of rapamycin (mTOR) pathway, leads to even greater perturbations in lipids and higher requirement for lipid-lowering therapy [46]. While direct and indirect influences of these agents may be potentially harmful to the heart, some investigators have implicated calcineurin in the development of left ventricular hypertrophy and heart failure in animal models [47]. The role of immunosuppression in the prevention or conversely the development of type 3 CRS needs further study.

5. Management of Chronic Reno-Cardiac Syndrome (Type 4)

The management of type 4 CRS is a multifaceted approach focusing on the reduction of cardiovascular risk factors and complications common to CKD patients. These include, but are not limited to, anemia, hypertension, altered bone, and mineral metabolism, dyslipidemia, smoking, albuminuria and malnutrition [48, 49]. Several therapies targeting such uremic complications as anemia, homocysteine, calcium-phosphate product and hyperparathyroidism are supported by observational studies demonstrating the association between adverse cardiovascular events and these conditions.

 In observational studies, the treatment of anemia seems to lessen cardiovascular events, however this has not been borne out in randomized trials where higher hemoglobin targets have been associated with worse outcomes [50–53]. Hence, the use of erythropoiesis-stimulating agents to prevent type 4 CRS seems to be ineffective. Elevated homocysteine has been associated with worsening cardiovascular outcomes in a number of observational studies [54], and has been a target of study in CKD. However, vitamin therapy to lower homocysteine has been unhelpful in patients with advanced CKD [55, 56] and harmful in patients with diabetes and more moderate CKD [57].

 Observational studies have implicated elevated calcium-phosphate product, elevated phosphate, elevated parathyroid
hormone, and inadequate vitamin D receptor activation as potential risk factors for type 4 CRS [58–60]. Clinical trials to date have been generally disappointing. A meta-analysis of trials studying the use of the phosphate binder sevelamer indicated no significant benefit of therapy [61]. However, a subgroup analysis in older patients at higher cardiovascular risk suggests that phosphate binding may improve outcomes [62] and intensive lowering of calcium-phosphate product improves levels of C-reactive protein [63]. With respect to parathyroid hormone, high levels have been associated with adverse cardiovascular outcomes in CKD [59], and a systematic review revealed that cinacalcet, a drug used to lower parathyroid hormone, decreased hospitalizations related to cardiovascular disease [64]. A large randomized trial of cinacalcet is examining hard cardiovascular endpoints and mortality [65], and trials of phosphate binders and vitamin D analogs are ongoing.

The use of “statins” (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) is a cornerstone of risk factor modification in patients at risk for cardiac disease. Unfortunately, two high-profile negative trials in dialysis patients [66, 67] have cast a shadow of doubt over the use of statins to prevent type 4 CRS, at least in advanced CKD patients. The recently published Study of Heart and Renal Protection (SHARP) included 3,023 dialysis patients and 6,247 CKD patients not on dialysis, and preliminary results showed that a combination of simvastatin and ezetimibe lowered the risk of major atherosclerotic events, with a risk ratio of 0.83 (0.74–0.94, \( P = .0022 \)) [68]. Of interest, the subgroup of patients on dialysis seemed to experience less of a benefit from the drug therapy, and all-cause mortality was unaffected. The full publication is eagerly awaited. In an earlier meta-analysis [69] Strippoli et al. demonstrated significant reductions in cardiovascular end points in CKD patients treated with statins, though again all-cause mortality was unchanged. Statins did not, however, cause adverse events in subjects with CKD compared to those with normal kidney function, and the SHARP study indicated that the combination of simvastatin and ezetimibe in this population was well tolerated with no hepatoxic or myopathic complications.

6. Management of Secondary Cardiorenal Syndrome (Type 5)

Examples of type 5 CRS include a heterogeneous group of disorders, such as sepsis, systemic lupus erythematosus, amyloidosis, and diabetes mellitus [70]. It is difficult to formulate a treatment strategy to encompass all of these disorders, but more important is the recognition that injury to one organ is likely to influence or injure the other organ, and vice versa. Therapies directed to the improvement in function of one organ need to consider the interaction with, and role of, the other.

As sepsis is one of the more common acute disorders that involves multiple organs, and often causes codyfunction of kidneys and heart, it provides a suitable example for the discussion of type 5 CRS and its management. The study of early goal-directed therapy by Rivers et al. demonstrated that early intervention significantly decreased in-hospital death due to cardiovascular collapse by approximately half (21.0 versus 10.3%; \( P = .02 \)), and another study of protocol-driven targets in patients with septic shock [71] showed a significant reduction in the incidence of acute renal failure from 55.2% to 38.9% (\( P = .015 \)). De Backer and colleagues compared dopamine with norepinephrine in the management of shock (the majority with septic shock) and found that the dopamine group had a higher incidence of cardiac arrhythmia, while displaying a trend towards greater dependence on renal replacement therapy [72]. Additionally, an important randomized study of conservative versus liberal fluid resuscitation in patients with acute lung injury [73] found that the more conservative strategy improved not only outcomes related to lung injury itself, such as oxygenation and ventilator days, but this strategy also led to less cardiovascular failure and a trend towards improved renal outcomes. Intriguingly, animal studies indicate that in spite of increased coronary and renal blood flow, these organs demonstrate diminished function in sepsis [74]. Another study indicated that low-dose vasopressin was effective in limiting cardiac and kidney injury in sepsis [75]. Recognition of type 5 CRS as an entity in sepsis and other systemic disorders will allow further research into the signalling and mechanisms of injury and allow for the development of rational and effective therapies.

7. Conclusions

The subtypes of CRS discussed in this paper present unique management challenges, but also opportunities for further research. Sadly, many pivotal heart failure trials of the past decades which have been instrumental in guiding therapy for millions of patients worldwide have systematically excluded patients with acute or chronic kidney disease, making it difficult to provide evidence-based treatment guidelines for type 1 and 2 CRS. The recognition of acute kidney injury as an important clinical outcome, coupled with more stringent and standardized diagnostic criteria, has led to a tremendous increase in research activity in recent years. The increased understanding of downstream consequences of acute kidney injury, and in particular its role in type 3 CRS, has only recently been appreciated. Clearly more high-quality research in this area is necessary. Finally, an astonishing number of cardioprotective trials in type 4 CRS have been negative [76]. This underscores the need to recognize CKD as a factor that not only heightens risk of cardiovascular disease, but also modifies (or even negates) the effect of treatments proven effective in other populations. Understanding the complex bidirectional interactions between the heart and the kidneys can only help foster future drug development and investigations into the prevention and management of all subtypes of CRS.

References

[1] A. Flynn, B. Chokkalingam Mani, and P. J. Mather, “Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms,” Heart Failure Reviews, vol. 15, no. 5, pp. 605–611, 2010.
[2] S. M. Bagshaw, S. Uchino, R. Bellomo et al., “Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes,” *Clinical Journal of the American Society of Nephrology*, vol. 2, no. 3, pp. 431–439, 2007.

[3] S. A. Hunt, W. T. Abraham, M. H. Chin et al., “2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,” *Journal of the American College of Cardiology*, vol. 53, no. 15, pp. e1–e90, 2009.

[4] M. Jessup and M. R. Costanzo, “The cardiorenal syndrome. Do we need a change of strategy or a change of tactics?” *Journal of the American College of Cardiology*, vol. 53, no. 7, pp. 597–599, 2009.

[5] K. Dickstein, A. Cohen-Solal, G. Filippatos et al., “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM),” *European Journal of Heart Failure*, vol. 10, no. 10, pp. 933–989, 2008.

[6] K. Damman, G. Navis, T. D. J. Smilde et al., “Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction,” *European Journal of Heart Failure*, vol. 9, no. 9, pp. 872–878, 2007.

[7] W. Mullens, Z. Abrahams, H. N. Skouri et al., “Elevated intrabdominal pressure in acute decompensated heart failure. A potential contributor to worsening renal function?” *Journal of the American College of Cardiology*, vol. 51, no. 3, pp. 300–306, 2008.

[8] D. R. Salvador, N. R. Rey, G. C. Ramos, and F. E. Punzalan, “Continuous infusion versus bolus injection of loop diuretics in congestive heart failure,” *Cochrane Database of Systematic Reviews*, no. 1, article CD003178, 2004.

[9] H. Madkour, M. Gadallah, B. Riveline, G. E. Plante, and S. G. Masary, “Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension,” *American Journal of Nephrology*, vol. 15, no. 3, pp. 251–255, 1995.

[10] J. M. Testani, J. Chen, B. D. McCauley, S. E. Kimmel, and R. P. Shannon, “Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival,” *Circulation*, vol. 122, no. 3, pp. 265–272, 2010.

[11] R. V. Shah and M. M. Givertz, “Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome,” *Current Heart Failure Reports*, vol. 6, no. 3, pp. 176–181, 2009.

[12] J. T. Heywood, “The cardiorenal syndrome: lessons from the ADHERE database and treatment options,” *Heart Failure Reviews*, vol. 9, no. 3, pp. 195–201, 2005.

[13] M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al., “Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure,” *Journal of the American College of Cardiology*, vol. 49, no. 6, pp. 675–683, 2007.

[14] C. A. den Uil, W. K. Lagrand, S. D. A. Valk, P. E. Spronk, and M. L. Simoons, “Management of cardiogenic shock: focus on tissue perfusion,” *Current Problems in Cardiology*, vol. 34, no. 8, pp. 330–349, 2009.

[15] V. Schulz, R. Bonn, and J. Kindler, “Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure,” *Klinische Wochenschrift*, vol. 57, no. 5, pp. 243–247, 1979.

[16] W. Mullens, Z. Abrahams, G. S. Francis et al., “Sodium nitroprusside for advanced low-output heart failure,” *Journal of the American College of Cardiology*, vol. 52, no. 3, pp. 200–207, 2008.

[17] S. Reichert and A. Ignaszewski, “Molecular and physiological effects of nesiritide,” *Canadian Journal of Cardiology*, vol. 24, supplement, pp. 15B–18B, 2008.

[18] J. D. Sackner-Bernstein, H. A. Skopicki, and K. D.Aaronson, “Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure,” *Circulation*, vol. 111, no. 12, pp. 1487–1491, 2005.

[19] A. F. Hernandez, C. M. O’Connor, R. C. Starling et al., “Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF),” *American Heart Journal*, vol. 157, no. 2, pp. 271–277, 2009.

[20] M. S. Cuffe, R. M. Califf, K. F. Adams et al., “Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 287, no. 12, pp. 1541–1547, 2002.

[21] M. B. Yilmaz, K. Yalta, C. Yontar et al., “Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine,” *Cardiovascular Drugs and Therapy*, vol. 21, no. 6, pp. 431–435, 2007.

[22] A. Mebazaa, M. S. Nieminen, M. Packer et al., “Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial,” *Journal of the American Medical Association*, vol. 297, no. 17, pp. 1883–1891, 2007.

[23] N. S. Kirkby, P. W. F. Hadoke, A. J. Bagnall, and D. J. Webb, “The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?” *British Journal of Pharmacology*, vol. 153, no. 6, pp. 1105–1119, 2008.

[24] A. P. Coletta and J. G. F. Cleland, “Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology—WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME,” *European Journal of Heart Failure*, vol. 3, no. 6, pp. 747–750, 2001.

[25] J. J. Bax, B. Casadei, C. Di Mario et al., “Highlights of the 2009 scientific sessions of the European society of cardiology,” *Journal of the American College of Cardiology*, vol. 54, no. 25, pp. 2447–2458, 2009.

[26] M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr et al., “Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials,” *Journal of the American Medical Association*, vol. 297, no. 12, pp. 1332–1343, 2007.

[27] S. G. Coca, H. M. Krumholz, A. X. Garg, and C. R. Parikh, “Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease,” *Journal of the American Medical Association*, vol. 296, no. 11, pp. 1377–1384, 2006.

[28] S. Ljungman, J. Kjekshus, and K. Swedberg, “Renal function in patients hospitalized for acute decompensated heart failure,” *Heart Failure Reviews*, vol. 296, no. 11, pp. 1377–1384, 2007.

[29] V. Schulz, R. Bonn, and J. Kindler, “Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure,” *Klinische Wochenschrift*, vol. 57, no. 5, pp. 243–247, 1979.
[29] B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999.

[30] B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003.

[31] D. N. Juurlink, M. M. Mamdani, D. S. Lee et al., “Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study,” New England Journal of Medicine, vol. 351, no. 6, pp. 543–551, 2004.

[32] D. T. Ko, D. N. Juurlink, M. M. Mamdani et al., “ Appropriateness of spironolactone prescribing in heart failure patients: a population-based study,” Journal of Cardiac Failure, vol. 12, no. 3, pp. 205–210, 2006.

[33] H. Yorgun, A. Deniz, and K. Aytemir, “Cardiogenic shock secondary to combination of diltiazem and sotalol,” Internal Medicine Journal, vol. 38, no. 3, pp. 221–222, 2008.

[34] G. L. Bakris, P. Hart, and E. Ritz, “Beta blockers in the management of chronic kidney disease,” Kidney International, vol. 70, no. 11, pp. 1905–1913, 2006.

[35] P. Fu and M. O. Arcasoy, “Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis,” Biochemical and Biophysical Research Communications, vol. 354, no. 2, pp. 372–378, 2007.

[36] N. P. Riiksen, D. J. Hausenloy, and D. M. Yellon, “Erythropoietin: ready for prime-time cardioprotection,” Trends in Pharmacological Sciences, vol. 29, no. 5, pp. 258–267, 2008.

[37] D. S. Silverberg, D. Wexler, A. Iaino, S. Steinbruch, Y. Wollman, and D. Schwartz, “Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists,” International Urology and Nephrology, vol. 38, no. 2, pp. 295–310, 2006.

[38] A. Palazzuoli, D. S. Silverberg, F. Iovine et al., “Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome,” American Heart Journal, vol. 154, no. 4, pp. 645.e9–645.e15, 2007.

[39] J. K. Ghali, I. S. Anand, W. T. Abraham et al., “Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia,” Circulation, vol. 117, no. 4, pp. 526–535, 2008.

[40] S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009.

[41] R. L. Mehta, M. T. Pascual, S. Soroko, and G. M. Chertow, “Diuretics, mortality, and nonrecovery of renal function in acute renal failure,” Journal of the American Medical Association, vol. 288, no. 20, pp. 2547–2553, 2002.

[42] D. Jasuja, M. K. Mor, K. C. Hartwig, P. M. Palevsky, M. J. Fine, and S. D. Weisbord, “Provider knowledge of contrast-induced acute kidney injury,” American Journal of the Medical Sciences, vol. 338, no. 4, pp. 280–286, 2009.

[43] P. M. Palevsky, “Defining contrast-induced nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 7, pp. 1151–1153, 2009.

[44] R. J. Solomon, R. Mehran, M. K. Natarajan et al., “Contrast-induced nephropathy and long-term adverse events: cause and effect?” Clinical Journal of the American Society of Nephrology, vol. 4, no. 7, pp. 1162–1169, 2009.

[45] A. Webster, R. C. Woodroffe, R. S. Taylor, J. R. Chapman, and J. C. Craig, “Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients,” Cochrane Database of Systematic Reviews, no. 4, article CD003961, 2005.

[46] T. S. Larson, P. G. Dean, M. D. Stegall et al., “Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus,” American Journal of Transplantation, vol. 6, no. 3, pp. 514–522, 2006.

[47] Y. Sakata, T. Masuyama, K. Yamamoto et al., “Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats,” Circulation, vol. 102, no. 18, pp. 2269–2275, 2000.

[48] H. J. Manley, “Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management,” Journal of Managed Care Pharmacy, vol. 13, no. 9, supplement, pp. S6–S12, 2007.

[49] P. A. McCullough, C. T. Jurkowitz, P. E. Pergola et al., “Independent components of chronic kidney disease as a cardiovascular risk state: results from the kidney early evaluation program (KEEP),” Archives of Internal Medicine, vol. 167, no. 11, pp. 1122–1129, 2007.

[50] A. K. Singh, L. Szczek, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006.

[51] T. B. Drücke, F. Locatelli, N. Glyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006.

[52] A. Besarab, D. A. Goodkin, and A. R. Nissenson, “Normal Hematocrit Cardiac Trial Authors: the normal hematocrit study—follow-up,” New England Journal of Medicine, vol. 358, no. 4, pp. 433–434, 2008.

[53] M. A. Pfeffer, E. A. Burdmann, C. Y. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009.

[54] B. L. Urquhart and A. A. House, “Assessing plasma total homocysteine in patients with end-stage renal disease,” Peritoneal Dialysis International, vol. 27, no. 5, pp. 476–488, 2007.

[55] E. M. Wrone, J. M. Hornberger, J. L. Zehnder, L. M. McCann, N. S. Coplon, and S. P. Fortmann, “Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 420–426, 2004.

[56] R. L. Jamison, P. Hartigan, J. S. Kaufman et al., “Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial,” Journal of the American Medical Association, vol. 298, no. 10, pp. 1163–1170, 2007.

[57] A. A. House, M. Eliasziw, D. C. Cattran et al., “Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 303, no. 16, pp. 1603–1609, 2010.

[58] S. Mathew, M. Davies, R. Lund, G. Saab, and K. A. Hruska, “Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease,” European Journal of Clinical Investigation, vol. 36, no. 2, pp. 43–50, 2006.
S. K. Ganesh, A. G. Stack, N. W. Levin, T. Hulbert-Shearon, and F. K. Port, “Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2131–2138, 2001.

D. L. Andress, “Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation,” Kidney International, vol. 69, no. 1, pp. 33–43, 2006.

M. Tonelli, N. Wiebe, B. Culleton et al., “Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients,” Nephrology Dialysis Transplantation, vol. 22, no. 10, pp. 2856–2866, 2007.

W. N. Suki, R. Zabaneh, J. L. Cangiano et al., “Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients,” Kidney International, vol. 72, no. 9, pp. 1130–1137, 2007.

E. Movilli, A. Feliciani, C. Camerini et al., “A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients,” Nephron. Clinical Practice, vol. 101, no. 4, pp. c161–167, 2005.

R. Garside, M. Pitt, R. Anderson et al., “The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation,” Health Technology Assessment, vol. 11, no. 18, pp. 1–167, 2007.

G. M. Chertow, L. B. Pupim, G. A. Block et al., “Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 5, pp. 898–905, 2007.

C. Wanner, V. Krane, W. März et al., “Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis,” New England Journal of Medicine, vol. 353, no. 3, pp. 238–248, 2005.

B. C. Fellström, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” New England Journal of Medicine, vol. 360, no. 14, pp. 1395–1407, 2009.

C. Baigent and M. Landray, “The Results of the Study of Heart and Renal Protection (SHARP),” American Society of Nephrology Renal Week, Denver, Colo, USA, 2010.

G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., “Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials,” British Medical Journal, vol. 336, no. 7645, pp. 645–651, 2008.

A. A. House, I. Anand, R. Bellomo et al., “Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference,” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1416–1420, 2010.

S. Shastri and M. J. Sarnak, “Cardiovascular disease and CKD: core curriculum 2010,” American Journal of Kidney Diseases, vol. 56, no. 2, pp. 399–417, 2010.